APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
时间：2024-12-07 05:05:00 市场： 美股 综合
Apellis Pharmaceuticals Inc : TD Cowen Cuts Target Price to $60 From $95
时间：2024-11-06 13:31:50 市场： 美股 综合
Apellis Pharmaceuticals Inc : Piper Sandler Cuts Target Price to $32 From $40
时间：2024-11-06 11:54:44 市场： 综合 美股
Apellis Pharmaceuticals Q3 Operating Expenses USD 244.11 Million
时间：2024-11-05 20:05:00 市场： 美股 综合
Apellis Pharmaceuticals Inc - to Submit Supplemental Nda to FDA in Early 2025
时间：2024-10-27 02:00:00 市场： 综合 美股
Apellis Pharmaceuticals Inc - All Secondary Endpoints Favored Pegcetacoplan Treatment
时间：2024-10-27 02:00:00 市场： 综合 美股
Pivotal Valiant Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients With C3g / Primary Ic-Mpgn
时间：2024-10-27 02:00:00 市场： 美股 综合
Apellis Pharmaceuticals Inc : Wedbush Cuts Target Price to $27 From $35
时间：2024-10-17 19:36:54 市场： 综合
Apellis Pharmaceuticals Inc : William Blair Initiates Coverage With Outperform Rating; Fair Value Estimate $50
时间：2024-10-16 19:06:13 市场： 美股 综合
Apellis Announces Oral Presentation at American Society of Nephrology (Asn) Kidney Week on Phase 3 Valiant Study of Pegcetacoplan in C3g and Primary Ic-Mpgn
时间：2024-10-16 19:00:02 市场： 美股